Wallace Carol A, Ravelli Angelo, Huang Bin, Giannini Edward H
Division of Immunology, Rheumatology, and Infectious Disease, Children's Hospital and Regional Medical Center, Seattle, Washington 98105, USA.
J Rheumatol. 2006 Apr;33(4):789-95. Epub 2006 Feb 15.
To begin the validation process of the preliminary criteria for inactive disease (ID), clinical remission on medication (CRM), and clinical remission off medication (CR) in children with select forms of juvenile idiopathic arthritis (JIA).
We used the OMERACT filter paradigm to estimate the validity of the criteria within each of the filter's 3 components: truth, discrimination, and feasibility, in 5 categories of JIA: systemic arthritis, persistent and extended oligoarthritis, and rheumatoid factor-positive and negative polyarthritis. Data sources for determining validity estimates included a Delphi questionnaire survey sent to 246 pediatric rheumatologists in 34 countries, a consensus conference attended by 20 senior pediatric rheumatologists representing 9 countries, a retrospective chart review of 437 patients with JIA from 3 tertiary care clinics who had been followed between 4 and 22 years, and the literature.
Truth component: face and content validity. These aspects of validity were largely established via the Delphi questionnaire exercise and the consensus conference. Using an 80% consensus level, participants felt that a set of non-redundant variables could effectively differentiate the clinical states of ID, CRM, and CR. Criterion validity could not be irrefutably established because no gold standard for inactive disease exists for JIA. As an alternative, published investigations of remission in JIA were used to estimate concurrent and convergent validity, as surrogates for criterion validity and as indicators of overall construct validity. Correlational analyses revealed the new criteria to have good construct validity. Discrimination component: the criteria demonstrated moderate to high levels of classification, prognosis, and responsiveness (sensitivity to change) using data from the chart review. Patients who were able to attain CR remained disease-free for substantially longer periods than did those who attained only ID or CRM. Responsiveness was evidenced by the ability of the criteria to allow movement of most patients between the disease states, consistent with what is known of the course of the disease. Feasibility component: Results of the Delphi and consensus conference produced a set of criteria that are easily, quickly, and inexpensively completed in the physician's office, and present minimal or no risk to the patient.
The preliminary criteria demonstrated moderate to excellent validity characteristics in some, but not all components of the OMERACT filter. Prospective validation studies are under way.
对特定类型幼年特发性关节炎(JIA)患儿的疾病静止(ID)、药物治疗临床缓解(CRM)及停药临床缓解(CR)初步标准开始进行验证。
我们采用OMERACT筛选范式,在JIA的5种类型中,即全身型关节炎、持续性和扩展性少关节炎、类风湿因子阳性和阴性多关节炎,对筛选的3个组成部分(真实性、区分性和可行性)中的每一项标准的有效性进行评估。用于确定有效性评估的数据来源包括向34个国家的246名儿科风湿病学家发送的德尔菲问卷调查、由代表9个国家的20名资深儿科风湿病学家参加的共识会议、对来自3家三级医疗诊所的437例JIA患者进行的回顾性病历审查(这些患者接受了4至22年的随访)以及文献资料。
真实性部分:表面效度和内容效度。效度的这些方面主要通过德尔菲问卷调查和共识会议得以确立。采用80%的共识水平,参与者认为一组非冗余变量能够有效区分ID、CRM和CR的临床状态。由于JIA不存在疾病静止的金标准,因此无法确凿地确立标准效度。作为替代方法,利用已发表的关于JIA缓解情况的研究来估计同时效度和聚合效度,作为标准效度的替代指标以及整体结构效度的指标。相关性分析显示新标准具有良好的结构效度。区分性部分:使用病历审查数据,这些标准显示出中等至高程度的分类、预后和反应性(对变化的敏感性)。能够达到CR的患者保持无病状态的时间比仅达到ID或CRM的患者长得多。标准能够使大多数患者在疾病状态之间转换,这与已知的疾病病程相符,从而证明了反应性。可行性部分:德尔菲调查和共识会议的结果产生了一组在医生办公室易于、快速且低成本完成的标准,并且对患者的风险极小或没有风险。
初步标准在OMERACT筛选的部分而非所有组成部分中显示出中等至优异的效度特征。前瞻性验证研究正在进行中。